CapsoVision (CV) Registration Filing summary

Company overview and business model

• Commercial-stage medical technology company focused on capsule endoscopy solutions for GI tract diagnostics, leveraging advanced imaging and AI technologies.

• Core products include CapsoCam Plus (small bowel) and CapsoCam Colon (colon), both offering 360° panoramic imaging and cloud-based data management.

• CapsoCam Plus is FDA-cleared for small bowel use; CapsoCam Colon is pending FDA clearance, with commercialization targeted for 2H 2026 in the U.S. and early 2027 in the EU.

• Revenue is primarily generated from direct sales to providers in the U.S. and through distributors internationally, with a growing direct sales presence in key markets like Germany.

• The company is expanding into new indications, including pediatric use, telemedicine, and future feasibility studies for esophageal and pancreatic cancer screening.

Financial performance and metrics

• Revenue grew from $9.8M in 2023 to $11.8M in 2024 (21% YoY growth); Q1 2025 revenue was $2.8M, up 12% YoY.

• Gross margin was 54% in 2024, down slightly from 56% in 2023; operating losses increased to $19.9M in 2024 from $11.3M in 2023.

• Net loss for 2024 was $19.9M; accumulated deficit as of March 31, 2025 was $135.7M.

• Cash balance as of March 31, 2025 was $4.4M; pro forma as adjusted cash post-IPO is projected at $27.2M.

• Customer retention rate was approximately 90% in 2024; over 135,000 patients have used CapsoCam Plus worldwide.

Use of proceeds and capital allocation

• Estimated net proceeds of $22.8M (at $5.25/share midpoint) to be used for R&D (approx. $8M), repayment of a $1M investor loan, and general corporate purposes.

• R&D focus includes CapsoCam Plus AI, CapsoCam Colon, and clinical studies for new GI indications.

• Management has discretion over allocation; proceeds may be invested in capital-preservation instruments pending use.